EYENOVIA INC. - COMMO

0,5002

06-ноября-24 15:59:53

15 мин. задержка

Акции

-0,0076

-1,50%

Сегодняшний диапазон

0,4886 - 0,5200

ISIN

N/A

Источник

NASDAQ

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

23 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

16 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

01 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

27 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

26 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

03 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Closing of Public Offering

23 авг 2024 11:42:23 Источник Nasdaq GlobeNewswire
Eyenovia Announces Pricing of $5.14 Million Public Offering

21 авг 2024 09:29:09 Источник Nasdaq GlobeNewswire
Eyenovia, Inc. Announces Proposed Public Offering

20 авг 2024 17:09:50 Источник Nasdaq GlobeNewswire
Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

13 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

08 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

07 авг 2024 17:11:42 Источник Nasdaq GlobeNewswire
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

30 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

23 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Announces Pricing of $5M Registered Direct Offering

28 июн 2024 08:00:14 Источник Nasdaq GlobeNewswire
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

15 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

25 апр 2024 07:00:01 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.